Medical Genetics FDA (USA) took this action after it learned that a second child treated in a french gene therapy trial had developed a leukemia-like conditionMedical Genetics FDA (USA) took this action after it learned that a second child treated in a French gene therapy trial had developed a leukemia-like condition